MADISON, WISCONSIN — ReCellerate, Inc., is excited to announce the upcoming start of a 36-horse study to measure EquiFlow’s (Concentrated Equine Protein Serum) effectiveness to combat Exercise Induced Pulmonary Hemorrhage (EIPH) in barrel racing horses that suffer from bleeding during competition or strenuous exercise.
Press release courtesy Recellerate
Thanks to the gracious efforts and generosity of Keith & Dee Burgess (Riverton, WY) and Stover Farms (Dallas, GA) the study is fully funded with no-cost to horse owners that participate.
Dr. Warwick Bayly, PhD, BvSc, a Professor of Equine Medicine at Washington State University’s College of Veterinary Medicine and an internationally recognized expert in the field of EIPH will serve as Principal Investigator and administer the study. The study is slated for June 2025 and will be conducted at Amie & Abbie Crews’ Three Rivers Arena in Glen Rose, Texas.
This marks the second consecutive year that ReCellerate has sponsored and conducted a large-scale study of its investigational EquiFlow product. Over the past year EquiFlow has been the centerpiece of a 30-horse clinical investigation at Rood & Riddle Equine Hospital in Lexington, Kentucky that has focused on the reduction of upper airway inflammation and mucus. The results collected to date show that the product is a safe and effective stem cell derived biologic for equine respiratory health. Upon completion the study results will be submitted for scientific review and publication.
EquiFlow has already been shown to be very effective in several proof of concept and field studies lowering the incidence of bleeding from EIPH while simultaneously suggesting its possible use as an aid in recovery from lung inflammation in high performance horses such as Thoroughbred racehorses, barrel racing horses, polo ponies and American Saddlebreds.
- EIPH and Lasix with Dr. Melissa Fenn
- What is EquiFlow™, and Will it Change the Game for Upper Airway Inflammation and Mucus in Performance Horses?
EquiFlow is a concentrated equine protein serum product that is sourced from the stem cells of qualified donor horses. The product is administered right in the stall by nebulizer ensuring that it reaches the injury site in the horse’s lungs. ReCellerate is pursuing veterinary drug approval from the U.S. Food and Drug Administration (FDA) that will establish the product as a safe and effective no-needle alternative to existing treatments in the market today. Treating the problem, rather than just reducing the symptoms, leads to consistent outcomes in performance.
Learn more about recellerate here.
If you believe you have a horse with EIPH that bleeds during strenuous exercise that could benefit by being in this no-cost study, please contact ReCellerate at info@recellerate.com.
Contact:
Chris Grove
chris.grove@recellerate.com
